Portal de Periódicos da CAPES

Adalimumab therapy in rheumatoid arthritis

2004; Elsevier BV; Volume: 30; Issue: 2 Linguagem: Inglês

10.1016/j.rdc.2004.02.004

1558-3163

Edward Keystone, Boulos Haraoui,

Monoclonal and Polyclonal Antibodies Research

Adalimumab is a recombinant human immunoglobulin G1 monoclonal antibody that is specific for human tumor necrosis factor. Based on the data presented in this article, adalimumab administered alone or in patients partially responsive to methotrexate exhibits a rapid onset of action, provides a substantial reduction in signs and symptoms, and results in an improvement in physical function and health-related quality of life. Adalimumab has been demonstrated to inhibit progression of structural joint damage in patients who have long-standing rheumatoid arthritis. Taken together, the data support adalimumab as a new therapeutic option for patients with moderate to severe rheumatoid arthritis.